Sildenafil and Cardioprotection

Author(s): Rakesh C. Kukreja.

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 39 , 2013

Become EABM
Become Reviewer

Abstract:

The phosphodiesterese-5 (PDE5) inhibitors, including sildenafil (Viagra™), vardenafil (Levitra™), tadalafil (Cialis™) and avanafil (Stendra™) have been developed for the treatment of erectile dysfunction. Moreover, sildenafil and tadalafil have been approved for the management of pulmonary arterial hypertension. A number of preclinical studies have shown that PDE5 inhibitors have powerful protective effect against several clinical scenarios including myocardial ischemia/reperfusion injury, doxorubicin and post-MI, heart failure, cardiac hypertrophy, heart transplantation, Duchenne muscular dystrophy and preconditioning of stem cells. Based on these studies, it appears that sildenafil and other PDE5 inhibitors hold promise for further development as novel drug therapies in cardioprotection.

Keywords: Ischemia, heart-failure, cardioprotection, phosphodiesterase-s, cGMP.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 19
ISSUE: 39
Year: 2013
Page: [6842 - 6847]
Pages: 6
DOI: 10.2174/138161281939131127110156
Price: $58

Article Metrics

PDF: 33